Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Financing Activities (2016 - 2025)

Editas Medicine (EDIT) has disclosed Cash from Financing Activities for 11 consecutive years, with $17.2 million as the latest value for Q3 2025.

  • Quarterly Cash from Financing Activities changed N/A to $17.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $78.7 million through Sep 2025, up 7551.46% year-over-year, with the annual reading at $56.0 million for FY2024, 52.54% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was $17.2 million at Editas Medicine, up from $7.4 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $261.5 million in Q1 2021, with the low at -$1.4 million in Q1 2025.
  • Average Cash from Financing Activities over 5 years is $30.0 million, with a median of $838000.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities soared 31923.16% in 2023, then tumbled 848.44% in 2025.
  • Over 5 years, Cash from Financing Activities stood at $1.1 million in 2021, then tumbled by 41.44% to $619000.0 in 2022, then fell by 16.96% to $514000.0 in 2023, then soared by 10700.19% to $55.5 million in 2024, then tumbled by 69.07% to $17.2 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $17.2 million, $7.4 million, and -$1.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.